The key race: the first wave of approved cures is fighting for durable revenue while a second wave of AI-native entrants races to shorten the odds behind it
Biotech's founding-generation platforms, mRNA and gene editing, spent August proving their first products can hold a market rather than just clear a regulatory bar. Vertex Pharmaceuticals' cystic fibrosis franchise, still the industry's clearest example of a durable, high-margin cure, got its most direct competitive threat removed on August 10 when rival Sionna Therapeutics halted its add-on candidate SION-719 after it missed the primary endpoint in a Phase 2a trial against Vertex's own Trikafta; Sionna's stock lost roughly 90% of its value in a day while Vertex shares rose to an all-time high. One rung down the value chain, CRISPR Therapeutics keeps proving the harder point, that even a working one-time cure needs years to become a business: Casgevy has now passed 500 cumulative patient starts and reaches children as young as two, but that ramp still trails the roughly 60,000-plus eligible patients CRISPR and partner Vertex have identified worldwide.
The mRNA pioneers pushed the same question from the demand side. Moderna's approved mFlusiva flu shot became its fourth respiratory product on August 5, and on August 10 the company opened a Phase 1 trial of mRNA-1365, a combination shot targeting RSV and human metapneumovirus together in adults 60 and older, broadening the respiratory franchise it is counting on to offset a shrinking COVID base. Behind both platforms, a newer, AI-native cohort is racing to compress the industry's roughly 90% clinical failure rate before it ever needs a marketed product: San Francisco's Xaira Therapeutics, backed by a $1 billion launch round that is ARCH Venture Partners' largest investment in its 39-year history, and Earendil Labs, which raised $787 million in March 2026 on the strength of a $2.56 billion Sanofi partnership, are both still pre-clinical, meaning the platform generating the most capital in the sector right now has yet to prove it beats the odds the incumbents already know.
Who's ahead: Vertex widens its lead into endocrinology, CRISPR and Moderna diversify their pipelines, and BioNTech absorbs a leadership handoff mid-pivot
Vertex remains the sector's most complete story. Beyond the Sionna news, it is proceeding toward closing its roughly $10 billion acquisition of endocrine-disease specialist Crinetics Pharmaceuticals, its largest deal ever: the Hart-Scott-Rodino waiting period expired August 12, antitrust clearances are in hand from Austria, Germany and Australia, and a Crinetics shareholder vote is scheduled for August 28, putting the close on track for early September 2026 and adding the marketed acromegaly drug Palsonify plus an endocrinology pipeline the companies say could add $5 billion or more in combined peak revenue. CRISPR Therapeutics, which keeps roughly 40% of Casgevy's economics, is diversifying in parallel, having moved two more in vivo editing candidates, CTX340 for refractory hypertension and CTX460 from its new SyNTase platform, into Phase 1 in its August 3 update, with Phase 2 topline data for the Sirius Therapeutics-partnered siRNA candidate CTX611 still due in the second half of 2026.
BioNTech is absorbing the summer's most consequential leadership change mid-pivot: its supervisory board named Guido Oelkers, chief executive of Swedish Orphan Biovitrum, as the company's next CEO on August 3, succeeding founder Ugur Sahin no later than February 1, 2027, while Sahin's co-founder and wife Ozlem Tureci also departs. The handoff lands alongside a revenue miss and a roughly 20% cut to full-year guidance, plus a restructuring eliminating up to 1,860 manufacturing roles as COVID-vaccine sites in Germany and Singapore wind down, even as its up-to-$11.1 billion Bristol Myers Squibb partnership for the bispecific antibody BNT327 keeps expanding into a seven-trial pivotal program. A newer kind of entrant is also staking a claim from outside conventional pharma: Anthropic's April 2026 acquisition of drug-discovery startup Coefficient Bio for roughly $400 million now underpins Claude Science, an AI research workbench launched June 30 that connects Claude to more than 60 scientific databases and tools, alongside an internal Anthropic drug-discovery program targeting diseases too commercially unattractive for traditional biopharma.
What decides it: whether the system can pay for cures that already exist, and whether AI actually changes the odds rather than just the funding round
The gate separating today's approved gene and cell therapies from a mass-market industry was never really the science; the ISS-adjacent example of Casgevy's slow ramp against a huge eligible population shows the constraint is now payment infrastructure. CMS's Cell and Gene Therapy Access Model, which lets states pool risk and negotiate outcomes-based arrangements for high-cost one-time therapies, had reached 33 states plus DC and Puerto Rico by 2026, covering roughly 84% of the Medicaid sickle-cell population, a real structural fix moving in parallel with Casgevy's own commercial ramp. But the risk cuts both ways even after approval: 2025 brought the platform's first major commercial failures when Pfizer withdrew its hemophilia B gene therapy Beqvez and BioMarin withdrew Roctavian for hemophilia A after a roughly $240 million write-down, proof that regulatory clearance alone does not guarantee a therapy finds a payable market.
Whether AI-native drug discovery changes that calculus, rather than just adding another well-funded way to fail at the same rate, is still unresolved. Xaira, Earendil, and Anthropic's Claude Science all sit upstream of that question, applying generative models to protein and antibody design before a single asset from any of them has reached a pivotal trial; the sector's existing large financings, including Xaira's billion-dollar launch and Earendil's Sanofi-backed round, are pricing in an assumption about AI's clinical success rate that no company in this specific wave has yet tested with real trial data.
The money and the rules: an M&A and IPO rebound collides with Most-Favored-Nation pricing and a barely-preserved NIH budget
Capital kept arriving at a pace the sector has not seen since before the pandemic. Biopharma M&A totaled $96 billion across 80 deals in the first half of 2026, with $55.1 billion of that from 48 deals in the second quarter alone, and EY has called M&A and partnerships the defining story of the year as acquirers chase platform biotechs ahead of an estimated $300 billion of branded-drug patent expirations due by 2030. Public markets rewarded the sector on the way up too: 18 biotech IPOs priced in the first half of 2026, more than double all of 2025, and the XBI biotech index has returned more than 40% over the trailing year.
Policy is pulling in a genuinely mixed direction. The Trump administration's Most-Favored-Nation drug-pricing push has now landed deals with 17 leading manufacturers covering roughly 86% of the branded US drug market, offering a three-year tariff suspension to compliant companies in exchange for pricing concessions delivered through the TrumpRx.gov platform launched February 5, 2026, though the discounts mainly reach Medicaid and cash-pay patients rather than private insurance or Medicare. Research funding survived a scare rather than a cut: Congress rejected the administration's proposed roughly 40% reduction to the NIH budget and instead passed a final fiscal 2026 appropriation of $47.2 billion plus $7.4 billion for the National Cancer Institute on February 3, 2026, about 1% above fiscal 2025, though that came after an earlier round of grant terminations had already pulled roughly $9.5 billion in previously awarded research funding, a disruption the flat-to-up final number does not undo.
What to watch through 2027
The next several months carry a dense run of dated tests. Watch Vertex close its roughly $10 billion Crinetics acquisition in early September 2026 pending the August 28 shareholder vote, and watch BioNTech complete Guido Oelkers's handover to CEO no later than February 1, 2027 while filing its first-ever US oncology submission, for trastuzumab pamirtecan, in the second half of the year. Watch CRISPR Therapeutics report CTX611 (SRSD107) Phase 2 topline data and further zugo-cel and CTX310 readouts in the second half of 2026, and watch Moderna's INTerpath-001 melanoma Phase 3 data track toward a 2026-2027 readout as its new mRNA-1365 RSV/hMPV combination and mRNA-4194 Lynch-syndrome cancer-prevention programs move through early trials.
Further out, watch whether Xaira, Earendil, or Anthropic's internal Claude Science-driven programs produce this wave's first pivotal clinical data, the event that would finally test whether AI-native drug discovery beats the industry's historical odds rather than just outraising it. Watch whether CMS's Cell and Gene Therapy Access Model keeps closing the payment gap for approved therapies even as more one-time cures reach the market, and watch whether the Most-Favored-Nation pricing framework expands beyond its current 17 manufacturers or draws a serious legal or congressional challenge as more deals like the GLP-1 pricing agreement come into effect.
Sources
- The Motley Fool - Vertex Pharmaceuticals hits an all-time high after rival Sionna's trial failure
- Vertex Pharmaceuticals Q2 2026 results and Crinetics acquisition timeline (SEC 8-K)
- BioNTech (GlobeNewswire) - Appointment of Guido Oelkers as CEO
- USC Schaeffer Center - $2 million gene therapy cures require a financing model
- ASCO - Congress passes FY26 appropriations bill, preserving NIH funding
- The White House - Most-Favored-Nation drug pricing fact sheet
